Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients
- PMID: 34916254
- DOI: 10.1183/13993003.01702-2021
Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients
Conflict of interest statement
Conflict of interest: A.I. Papaioannou reports personal fees and non-financial support from Novartis, Elpen, Menarini, AstraZeneca, Boehringer Ingelheim and Chiesi, non-financial support from GSK, outside the submitted work. Conflict of interest: A. Photiades has nothing to disclose. Conflict of interest: M. Gaga reports grants from Chiesi, Novartis and Sanofi.
Comment on
-
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.Eur Respir J. 2021 Dec 16;58(6):2100413. doi: 10.1183/13993003.00413-2021. Print 2021 Dec. Eur Respir J. 2021. PMID: 34112734 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical